JP6568099B2 - カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法 - Google Patents

カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法 Download PDF

Info

Publication number
JP6568099B2
JP6568099B2 JP2016558395A JP2016558395A JP6568099B2 JP 6568099 B2 JP6568099 B2 JP 6568099B2 JP 2016558395 A JP2016558395 A JP 2016558395A JP 2016558395 A JP2016558395 A JP 2016558395A JP 6568099 B2 JP6568099 B2 JP 6568099B2
Authority
JP
Japan
Prior art keywords
antibody
cgrp
headache
subject
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016558395A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017510579A (ja
JP2017510579A5 (cg-RX-API-DMAC7.html
Inventor
マルセロ ビガル，
マルセロ ビガル，
サラ ウォルター，
サラ ウォルター，
ヘンリー スターン，
ヘンリー スターン，
マイケル チャン，
マイケル チャン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
Original Assignee
Teva Pharmaceuticals International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54141465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6568099(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceuticals International GmbH filed Critical Teva Pharmaceuticals International GmbH
Publication of JP2017510579A publication Critical patent/JP2017510579A/ja
Publication of JP2017510579A5 publication Critical patent/JP2017510579A5/ja
Priority to JP2019085486A priority Critical patent/JP6892891B2/ja
Application granted granted Critical
Publication of JP6568099B2 publication Critical patent/JP6568099B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
JP2016558395A 2014-03-21 2015-03-20 カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法 Active JP6568099B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019085486A JP6892891B2 (ja) 2014-03-21 2019-04-26 カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461968897P 2014-03-21 2014-03-21
US61/968,897 2014-03-21
US201462083809P 2014-11-24 2014-11-24
US62/083,809 2014-11-24
US201562119778P 2015-02-23 2015-02-23
US62/119,778 2015-02-23
PCT/US2015/021887 WO2015143409A1 (en) 2014-03-21 2015-03-20 Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019085486A Division JP6892891B2 (ja) 2014-03-21 2019-04-26 カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2017510579A JP2017510579A (ja) 2017-04-13
JP2017510579A5 JP2017510579A5 (cg-RX-API-DMAC7.html) 2018-05-31
JP6568099B2 true JP6568099B2 (ja) 2019-08-28

Family

ID=54141465

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016558395A Active JP6568099B2 (ja) 2014-03-21 2015-03-20 カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
JP2019085486A Active JP6892891B2 (ja) 2014-03-21 2019-04-26 カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
JP2020185826A Pending JP2021014464A (ja) 2014-03-21 2020-11-06 カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
JP2021090623A Pending JP2021121637A (ja) 2014-03-21 2021-05-28 カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
JP2024014955A Pending JP2024040245A (ja) 2014-03-21 2024-02-02 カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019085486A Active JP6892891B2 (ja) 2014-03-21 2019-04-26 カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
JP2020185826A Pending JP2021014464A (ja) 2014-03-21 2020-11-06 カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
JP2021090623A Pending JP2021121637A (ja) 2014-03-21 2021-05-28 カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
JP2024014955A Pending JP2024040245A (ja) 2014-03-21 2024-02-02 カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法

Country Status (27)

Country Link
US (3) US9896502B2 (cg-RX-API-DMAC7.html)
EP (2) EP3119431B1 (cg-RX-API-DMAC7.html)
JP (5) JP6568099B2 (cg-RX-API-DMAC7.html)
KR (4) KR20200126018A (cg-RX-API-DMAC7.html)
CN (3) CN111973740A (cg-RX-API-DMAC7.html)
AU (1) AU2015230933B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016021423A2 (cg-RX-API-DMAC7.html)
CA (1) CA2943551A1 (cg-RX-API-DMAC7.html)
CL (1) CL2016002375A1 (cg-RX-API-DMAC7.html)
DK (1) DK3119431T3 (cg-RX-API-DMAC7.html)
EA (1) EA201691787A1 (cg-RX-API-DMAC7.html)
ES (1) ES2974803T3 (cg-RX-API-DMAC7.html)
FI (1) FI3119431T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240159T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065397T2 (cg-RX-API-DMAC7.html)
IL (2) IL247853B (cg-RX-API-DMAC7.html)
LT (1) LT3119431T (cg-RX-API-DMAC7.html)
MX (2) MX378344B (cg-RX-API-DMAC7.html)
PE (2) PE20220337A1 (cg-RX-API-DMAC7.html)
PL (1) PL3119431T3 (cg-RX-API-DMAC7.html)
PT (1) PT3119431T (cg-RX-API-DMAC7.html)
RS (1) RS65360B1 (cg-RX-API-DMAC7.html)
SI (1) SI3119431T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400131T1 (cg-RX-API-DMAC7.html)
UA (1) UA123759C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015143409A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201606745B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
EP2380592B1 (en) 2005-11-14 2018-03-07 Teva Pharmaceuticals International GmbH Antagonist antibody directed against calcitonin gene-related peptide
ES2689322T3 (es) 2008-03-04 2018-11-13 Teva Pharmaceuticals International Gmbh Métodos para tratar el dolor crónico
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
HRP20240159T1 (hr) 2014-03-21 2024-04-12 Teva Pharmaceuticals International Gmbh Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
TW201725212A (zh) * 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
EP3589317A1 (en) 2017-03-02 2020-01-08 Beth Israel Deaconess Medical Center, Inc. Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide
EP3774881A1 (en) 2018-04-02 2021-02-17 Amgen Inc. Erenumab compositions and uses thereof
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
JOP20210156A1 (ar) 2019-01-08 2023-01-30 H Lundbeck As علاج إسعافي وعلاج سريع للصداع باستخدام أجسام مضادة لـ cgrp
US20220110887A1 (en) * 2019-02-08 2022-04-14 Schedule 1 Therapeutics, Inc. Compositions comprising cannabinoids and methods of use thereof
EP3962522A4 (en) * 2019-05-02 2023-07-19 H. Lundbeck A/S Treatment of headache using anti-cgrp antibodies
CN114127110B (zh) * 2019-05-30 2022-07-01 山东博安生物技术股份有限公司 抗cgrp抗体及其应用
AU2020202454A1 (en) * 2020-04-06 2021-10-21 H. Lundbeck A/S Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies
EP4157353A1 (en) * 2020-05-29 2023-04-05 Amgen Inc. Antibody formulations and uses thereof

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3662333A (en) 1970-09-08 1972-05-09 Bendix Corp Hydraulic accumulator charge detector and indicating system
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPS62129297A (ja) 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ES2200016T3 (es) 1989-03-21 2004-03-01 Vical Incorporated Expresion de secuencias polinucleotidicas exogenas en un vertebrado.
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
JPH04500688A (ja) 1989-07-10 1992-02-06 アミリン・コーポレイション 肥満および本態性高血圧および関連疾患の治療
WO1991002805A2 (en) 1989-08-18 1991-03-07 Viagene, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
ES2197145T3 (es) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services Transferencia de genes mediada por adenovirus al gastrointestinal.
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993025234A1 (en) 1992-06-08 1993-12-23 The Regents Of The University Of California Methods and compositions for targeting specific tissue
JPH09507741A (ja) 1992-06-10 1997-08-12 アメリカ合衆国 ヒト血清による不活性化に耐性のあるベクター粒子
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
AU6524794A (en) 1993-03-24 1994-10-11 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
EP0695169B1 (en) 1993-04-22 2002-11-20 SkyePharma Inc. Multivesicular cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
GB9316989D0 (en) 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
DE69433461T2 (de) 1993-09-15 2004-11-18 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Rekombinanter Alphavirus Vektor
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
HU223733B1 (hu) 1993-10-25 2004-12-28 Canji, Inc. Rekombináns adenovírus vektor és eljárás alkalmazására
KR100241300B1 (ko) 1993-11-16 2000-03-02 Sheldon A. Schaffer 활성물질의 조절된 방출성을 갖는 소포
JPH07196700A (ja) 1994-01-06 1995-08-01 Sando Yakuhin Kk 抗カルシトニン抗体及びその作製方法、並びに該抗体を用いたカルシトニンの測定方法
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
CA2158977A1 (en) 1994-05-09 1995-11-10 James G. Respess Retroviral vectors having a reduced recombination rate
JPH10504457A (ja) 1994-08-16 1998-05-06 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド カルシトニンレセプター
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
FR2732222B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
FR2732220B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2732598B1 (fr) 1995-04-10 1997-05-09 Oreal Utilisation de sel de metaux alcalino-terreux pour le traitement des prurits et des dysesthesies oculaires ou palpebraux
EP0737471A3 (fr) 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
WO1997009046A1 (en) 1995-09-05 1997-03-13 Smithkline Beecham Corporation Compounds and methods
WO1997041223A1 (en) 1996-04-15 1997-11-06 The University Of Miami Molecular clone of cgrp receptor component protein and uses thereof
AU2998597A (en) 1996-05-06 1997-11-26 Chiron Corporation Crossless retroviral vectors
US5746694A (en) 1996-05-16 1998-05-05 Wilk; Peter J. Endoscope biopsy channel liner and associated method
WO1998003534A1 (en) 1996-07-23 1998-01-29 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
WO1998009630A1 (en) 1996-09-09 1998-03-12 Smithkline Beecham Corporation Compounds and methods
US6344449B1 (en) 1996-09-10 2002-02-05 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
SE9704770D0 (sv) 1997-12-19 1997-12-19 Astra Ab New use
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
WO2000018764A1 (en) 1998-09-30 2000-04-06 Merck Sharp & Dohme Limited Benzimidazolinyl piperidines as cgrp ligands
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1031350A1 (en) 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
WO2000053211A2 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US20020162125A1 (en) 2001-03-06 2002-10-31 Anne-Marie Salmon Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
US7193070B2 (en) 2001-09-27 2007-03-20 Merck & Co., Inc. Isolated DNA molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods
US6767056B2 (en) 2002-01-14 2004-07-27 Shin Yeh Enterprise Co., Ltd. Settee with a foldable tray-support unit
CN1326879C (zh) 2002-03-29 2007-07-18 先灵公司 人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物
EP1501929B1 (de) 2002-05-06 2013-03-27 Noxxon Pharma AG Cgrp bindende nukleinsäuren
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US7097467B2 (en) 2002-06-03 2006-08-29 Wan-Tien Chen Dustproof plate fixture for an electrical connector
HUE032132T2 (en) 2002-06-05 2017-09-28 Bristol Myers Squibb Co Peptide receptor related to calcitonin gene
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
ES2323170T3 (es) 2002-08-12 2009-07-08 Birkir Sveinsson Uso de compuestos antagonistas del cgrp para el tratamiento de la psoriasis.
ZA200502612B (en) * 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
SI2263692T1 (sl) 2002-12-24 2020-10-30 Rinat Neuroscience Corp. Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo
US7288559B2 (en) 2003-03-14 2007-10-30 Merck + Co, Inc. Carboxamide spirohydantoin CGRP receptor antagonists
EP1605936B1 (en) 2003-03-14 2011-07-20 Merck Sharp & Dohme Corp. Aryl spirohydantoin cgrp receptor antagonists
AU2004222383B2 (en) 2003-03-14 2009-10-01 Merck Sharp & Dohme Corp. Bicyclic anilide spirohydantoin CGRP receptor antagonists
WO2004083187A1 (en) 2003-03-14 2004-09-30 Merck & Co. Inc. Monocyclic anilide spirohydantoin cgrp receptor antagonists
JP4584914B2 (ja) 2003-03-14 2010-11-24 メルク・シャープ・エンド・ドーム・コーポレイション ベノジアゼピンスピロヒダントインｃｇｒｐ受容体拮抗物質
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
DE602004027021D1 (de) 2003-04-15 2010-06-17 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
AU2004259675A1 (en) 2003-07-15 2005-02-03 Merck & Co., Inc. Hydroxypyridine CGRP receptor antagonists
US20080070239A1 (en) 2003-10-29 2008-03-20 University Of Rochester Detection of neureopeptides associated with pelvic pain disorders and uses thereof
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018794A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
CA2563687A1 (en) 2004-04-20 2005-11-03 Boehringer Ingelheim International Gmbh Use of a cgrp-antagonist combined with a serotonin-reuptake inhibitor in order to treat migraines
DE102004027912A1 (de) 2004-06-09 2005-12-29 Grünenthal GmbH Substituierte Cyclopenten-Verbindungen
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
TWI432196B (zh) 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20100144767A1 (en) 2005-08-25 2010-06-10 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
AU2006282799B2 (en) 2005-08-26 2012-11-29 Healthpartners Research & Education Methods for treatment of headaches by administration of oxytocin
CA2623648C (en) 2005-09-21 2018-05-22 The Regents Of The University Of California Systems, compositions, and methods for local imaging and treatment of pain
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
EP2380592B1 (en) 2005-11-14 2018-03-07 Teva Pharmaceuticals International GmbH Antagonist antibody directed against calcitonin gene-related peptide
JP2009515971A (ja) 2005-11-18 2009-04-16 メルク エンド カムパニー インコーポレーテッド スピロヒダントインアリールｃｇｒｐ受容体アンタゴニスト
WO2007076336A1 (en) 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
CA2658573A1 (en) 2006-07-21 2008-01-24 Vertex Pharmaceuticals Incorporated Cgrp receptor antagonists
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
CA2703364A1 (en) 2007-10-23 2009-04-30 Allergan, Inc. Methods of treating chronic neurogenic inflammation using modified clostridial toxins
ES2689322T3 (es) 2008-03-04 2018-11-13 Teva Pharmaceuticals International Gmbh Métodos para tratar el dolor crónico
BRPI0908276B8 (pt) 2008-03-04 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
CN101902988A (zh) 2008-04-25 2010-12-01 耐利克斯股份有限公司 支架移植物的输送系统
WO2010006168A2 (en) 2008-07-09 2010-01-14 University Of Rochester Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
BR112012004464B8 (pt) 2009-08-28 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
JO3330B1 (ar) 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
SG10201604040PA (en) 2011-05-20 2016-07-28 Alderbio Holdings Llc Anti-cgrp compositions and use thereof
CN103957935B (zh) 2011-05-20 2018-04-03 奥尔德生物控股有限责任公司 抗cgrp或抗cgrp‑r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
HRP20211873T1 (hr) * 2011-05-20 2022-03-04 H. Lundbeck A/S Proizvodnja visoke čistoće proteina s više podjedinica kao što su protutijela u transformiranim mikrobima kao što je pichia pastoris
JP6374789B2 (ja) 2011-05-20 2018-08-15 アルダーバイオ・ホールディングズ・エルエルシー 羞明または光嫌悪症を予防または抑制する抗ｃｇｒｐ抗体および抗体断片のそれを必要とする対象、特に片頭痛患者における使用
MX355890B (es) 2011-08-19 2018-05-03 Alderbio Holdings Llc Estrategia de múltiples copias para producción de alto título y alta pureza de proteínas de multi-subunidades tales como anticuerpos en microbios transformados tal como pichia pastoris.
US9163243B2 (en) 2012-01-10 2015-10-20 Noxxon Pharma Ag Nucleic acids specifically binding CGRP
US8722060B2 (en) 2012-05-23 2014-05-13 William J. Binder Method of treating vertigo
EP2912643A1 (en) 2012-10-29 2015-09-02 Net Entertainment NE AB Architecture for multi-player, multi-game, multi- table, multi-operator&multi-jurisdiction live casino gaming
CA2907570A1 (en) 2013-03-15 2014-09-18 Alder Biopharmaceuticals, Inc. Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
JP6412552B2 (ja) 2013-03-15 2018-10-24 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 酵母及び他の形質転換細胞中のポリペプチドの高収率発現のための温度シフト
MX374612B (es) 2013-07-03 2025-03-06 H Lundbeck As Star Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HRP20240159T1 (hr) 2014-03-21 2024-04-12 Teva Pharmaceuticals International Gmbh Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste
AU2015318008B2 (en) 2014-09-15 2021-05-20 Amgen Inc. Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
KR20180058777A (ko) 2015-09-24 2018-06-01 테바 파마슈티컬스 인터내셔널 게엠베하 (지속성) 외상후 두통의 예방, 치료 및 감소
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
CA3037661A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating cluster headache
MA53436A (fr) 2018-08-22 2021-12-01 Lilly Co Eli Anticorps anti-cgrp pour patients résistants au traitement

Also Published As

Publication number Publication date
LT3119431T (lt) 2024-03-12
KR20240146107A (ko) 2024-10-07
CL2016002375A1 (es) 2017-05-19
EP4324481A3 (en) 2024-05-01
SMT202400131T1 (it) 2024-05-14
ZA201606745B (en) 2022-12-21
EP4324481A2 (en) 2024-02-21
HK1232129A1 (en) 2018-01-05
CN111973740A (zh) 2020-11-24
NZ724442A (en) 2021-02-26
ES2974803T3 (es) 2024-07-01
MX2020012816A (es) 2021-02-15
US20190031745A1 (en) 2019-01-31
CN113244387A (zh) 2021-08-13
HRP20240159T1 (hr) 2024-04-12
AU2015230933B2 (en) 2020-08-13
CA2943551A1 (en) 2015-09-24
DK3119431T3 (da) 2024-03-18
KR20160147755A (ko) 2016-12-23
JP2017510579A (ja) 2017-04-13
RS65360B1 (sr) 2024-04-30
JP6892891B2 (ja) 2021-06-23
WO2015143409A1 (en) 2015-09-24
JP2021121637A (ja) 2021-08-26
US9896502B2 (en) 2018-02-20
SI3119431T1 (sl) 2024-06-28
CN106456759A (zh) 2017-02-22
EP3119431B1 (en) 2024-01-24
IL294490A (en) 2022-09-01
IL247853A0 (en) 2016-11-30
AU2015230933A1 (en) 2016-11-03
JP2024040245A (ja) 2024-03-25
MX2016012188A (es) 2017-04-27
JP2021014464A (ja) 2021-02-12
KR20220130822A (ko) 2022-09-27
KR20200126018A (ko) 2020-11-05
KR102274964B1 (ko) 2021-07-09
EA201691787A1 (ru) 2017-02-28
PE20161439A1 (es) 2017-01-26
FI3119431T3 (fi) 2024-03-20
IL247853B (en) 2022-08-01
UA123759C2 (uk) 2021-06-02
EP3119431A4 (en) 2017-09-06
EP3119431A1 (en) 2017-01-25
US11555064B2 (en) 2023-01-17
HUE065397T2 (hu) 2024-06-28
JP2019123750A (ja) 2019-07-25
MX378344B (es) 2025-03-10
NZ761478A (en) 2024-01-26
PE20220337A1 (es) 2022-03-14
PT3119431T (pt) 2024-04-16
US10519224B2 (en) 2019-12-31
PL3119431T3 (pl) 2024-06-24
US20150266948A1 (en) 2015-09-24
BR112016021423A2 (pt) 2017-11-14
US20200331991A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
JP6892891B2 (ja) カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
US20230235032A1 (en) Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same
JP5123197B2 (ja) カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体およびその使用方法
HK40041381A (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
BR122020017648B1 (pt) Composição para o tratamento ou redução da incidência de enxaqueca compreendendo um anticorpo monoclonal que inibe a via do peptídeo relacionado ao gene da calcitonina
HK1233955A1 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EA043536B1 (ru) Антагонистические антитела, направленные против пептида, кодируемого геном кальцитонина, и способы их применения
HK1237668A1 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HK1232129B (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HK40051844A (en) Antagonist antibodies directed against calcitonin gene-related peptide
NZ724442B2 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HK1227724A1 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HK1227724A (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161202

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20161121

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20161205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180412

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20180412

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190508

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190527

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190801

R150 Certificate of patent or registration of utility model

Ref document number: 6568099

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250